Key Summary Points

Cefiderocol is a new siderophore antibiotic. It has been built to overcome resistance in most of Gram-negative bacteria. New antibiotics have recently been released. However, treatment emerging resistance do appear. This is true for all new antibiotics and for a broad array of microbes.

We describe a case where cefidercol resistance does occur after a long antimicrobial treatment.

Even the newest antibiotic can be defeat by drug resistance. Although cefiderocol looks promising to treat MDR bacteria, resistance might occur. It should be used under strictly controlled conditions within an antimicrobial stewardship program and an infection control and prevention program to avoid loosing this new class of antibiotics.